Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

Southern Cross Pharma Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (263)
Cancellation by sponsor (201)
Prescription medicine registration (22)
Australian Public Assessment Report (AusPAR) (4)
Prescription medicine decision summary (1)
Section 14, TGO91 consent (1)

Date

2024 (16)
2023 (30)
2022 (102)
2021 (32)
2020 (52)
2019 (59)
2018 (35)
2017 (51)
2016 (22)
2015 (17)
2014 (9)
2013 (11)
2012 (19)
2011 (9)
2010 (10)
2009 (13)
2008 (3)
2007 (1)
2003 (1)

Results for "[search-keyword]"

Search

Sponsor content

492 result(s) found, displaying 41 to 50

LEVOTHYROXINE LUP levothyroxine sodium 150 microgram un-coated tablet blister pack (374931)

23 December 2022

ARTG

Australian Register of Therapeutic Goods (ARTG) information for LEVOTHYROXINE LUP levothyroxine sodium 150 microgram un-coated tablet blister pack.
APO-LEVOTHYROXINE levothyroxine sodium 50 microgram un-coated tablet blister pack (374892)

23 December 2022

ARTG

Australian Register of Therapeutic Goods (ARTG) information for APO-LEVOTHYROXINE levothyroxine sodium 50 microgram un-coated tablet blister pack.
MORPHINE MR MYLAN morphine sulfate pentahydrate 100 mg modified release tablet blister pack Cancelled under Section 30(1)(c) of the Act

28 June 2023

Cancellation by sponsor

Requested by Southern Cross Pharma Pty Ltd
MORPHINE MR MYLAN morphine sulfate pentahydrate 60 mg modified release tablet blister pack Cancelled under Section 30(1)(c) of the Act

28 June 2023

Cancellation by sponsor

Requested by Southern Cross Pharma Pty Ltd
MORPHINE MR MYLAN morphine sulfate pentahydrate 30 mg modified release tablet blister pack Cancelled under Section 30(1)(c) of the Act

28 June 2023

Cancellation by sponsor

Requested by Southern Cross Pharma Pty Ltd
MORPHINE MR MYLAN morphine sulfate pentahydrate 10 mg modified release tablet blister pack Cancelled under Section 30(1)(c) of the Act

28 June 2023

Cancellation by sponsor

Requested by Southern Cross Pharma Pty Ltd
BTC CLOPIDOGREL clopidogrel (as besilate) 75 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

28 June 2023

Cancellation by sponsor

Requested by Southern Cross Pharma Pty Ltd
ANASTROZOLE FBM anastrozole 1mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

28 June 2023

Cancellation by sponsor

Requested by Southern Cross Pharma Pty Ltd
LEVOTHYROXINE AJS levothyroxine sodium 125 microgram un-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

28 June 2023

Cancellation by sponsor

Requested by Southern Cross Pharma Pty Ltd
LEVOTHYROXINE AJS levothyroxine sodium 100 microgram un-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

28 June 2023

Cancellation by sponsor

Requested by Southern Cross Pharma Pty Ltd

Pages

First page
Previous page
Page 1
Page 2
Page 3
Page 4
Current page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.